Physician

Marco Adolfo Araneda, M.D.

According to 2025 Medicare claims, Marco Araneda, M.D. (NPI: 1336181502) practices hematology/oncology in the Brownsville-Harlingen, TX market, with the plurality of this provider's patient population coming from Cameron, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 78550-8321.

Araneda's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 365 traditional Medicare patients, billed 118,727 HCPCS/CPT codes, and received $1,847,510 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,404 prescription claims across 221 beneficiaries totaling $5,216,856 in drug costs, led by Pomalyst (Pomalidomide). 2018 DME data shows 12 claims. Open Payments data shows 46 records totaling $1,129. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,509,780 and ending at $1,847,510. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $2,230,125 to $5,216,856. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	501	198,582	$1,509,780
2016	527	182,274	$2,003,535
2017	635	171,137	$2,234,975
2018	664	229,424	$2,640,053
2019	633	210,995	$2,553,286
2020	519	134,849	$1,793,471
2021	482	138,477	$2,063,762
2022	458	137,203	$1,769,836
2023	414	114,484	$1,343,501
2024	365	118,727	$1,847,510

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	236	1,303	$2,230,125
2016	199	1,264	$2,335,177
2017	205	1,130	$2,089,881
2018	236	1,356	$2,831,028
2019	259	1,467	$3,176,347
2020	250	1,300	$3,356,053
2021	223	1,121	$3,138,049
2022	227	1,157	$3,502,215
2023	242	1,256	$4,956,334
2024	221	1,404	$5,216,856

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	129	$9,944
2016	12	171	$26,395
2017	N/R	44	$2,360
2018	N/R	12	$1,203
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	196	586	$88
82728	Ferritin (blood protein) level	111	203	$13
80053	Blood test, comprehensive group of blood chemicals	206	568	$10
36415	Insertion of needle into vein for collection of blood sample	174	552	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	201	731	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	43	1,204	$942,659
Revlimid	Lenalidomide	49	1,372	$842,231
Kisqali	Ribociclib Succinate	40	1,101	$555,987
Verzenio	Abemaciclib	16	448	$247,947
Stivarga	Regorafenib	13	364	$237,602

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	46	$1,129	Eisai Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Marco Adolfo Araneda, M.D.?

Tedicare shows public-source Medicare data for Marco Adolfo Araneda, M.D. (NPI 1336181502), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Marco Adolfo Araneda, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Marco Adolfo Araneda, M.D.?

Marco Adolfo Araneda, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Marco Adolfo Araneda, M.D. have Open Payments data?

Marco Adolfo Araneda, M.D. has 46 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.